Subscribe to RSS
DOI: 10.1055/s-0041-103535
Aktuelle Therapie der pulmonalen Hypertonie
Treatment of pulmonal hypertensionPublication History
Publication Date:
11 August 2015 (online)
Zusammenfassung
Während die klinische Klassifikation der Erkrankungen mit Pulmonaler Hypertonie (PH) in den letzten Jahren weitgehend stabil geblieben ist, haben sich die therapeutischen Möglichkeiten deutlich verbessert. Neben den allgemeinen Massnahmen (Impfungen, körperliches Training) existieren aktuell Empfehlungen zur Gabe von Diuretika, der Eisensubstitution sowie der oralen Antikoagulation. Zur gezielten medikamentösen Behandlung sind in den letzten Jahren einige neue Substanzen (in der Indikation Pulmonale Arterielle Hypertonie) zugelassen worden. Erstmalig steht nun auch eine medikamentöse Therapie für die nicht-operable und postoperativ persistierende Form der chronisch thromboembolische PH zur Verfügung.
Abstract
While the clinical classification of diseases with pulmonary hypertension (PH) has remained fairly stable in recent years, the treatment options have improved significantly. In addition to the General measures (vaccinations, physical training) new recommendations for supportive therapy (administration of diuretics, iron supplementation and oral anticoagulant) exist currently. Some new substances (mostly in the indication pulmonary arterial hypertension) have been admitted to the targeted drug treatment in recent years. For the first time, exist a approved drug therapy for the non-operable and residual chronic thromboembolic pulmonary hypertension.
-
Literatur
- 1 Galie N, Corris PA, Frost A et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D60-D72
- 2 Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263
- 3 Grünig E, Ehlken N, Hohenforst-Schmidt W et al. Allgemeine Therapie der pulmonal arteriellen Hypertonie. Dtsch Med Wochenschr 2014; 139: S136-S141
- 4 Klose H, Opitz C, Bremer H et al. Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH). Dtsch Med Wochenschr 2014; 139: S142-S150
- 5 Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42-D50
- 6 Vachiéry J-L, Adir Y, Barberà JA et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62: D100-D108
- 7 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Stand: August 2014 Epidemiologisches Bulletin; 2014. Nr. 34
- 8 Koehler U, Hildebrandt O, Jerrentrup L et al. Die Langzeit-Sauerstoff-Therapie (LTOT) – Was sollten Arzt, Versorger und Krankenkasse wissen?. Pneumologie 2014; 68: 193-198
- 9 Magnussen H, Hauck RW, Worth H, Herth FJ. Position zur Langzeit-Sauerstoffgabe. Pneumologie 2014; 68: 591-593
- 10 Olsson KM, Delcroix M, Ghofrani HA et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57-65
- 11 Pulido T, Adzerikho I, Channick RN et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818
- 12 Ghofrani HA, D‘Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329
- 13 Ghofrani HA, Galiè N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340
- 14 Wilkens H, Lang I, Blankenburg T et al. Chronisch thromboembolische pulmonale Hypertonie (CTEPH) 2014. Ein Positionspapier. Dtsch Med Wochenschr 2014; 139: S155-S165
- 15 Actelion. Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension. Im Internet http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1793163 Letzter Zugriff: 9.7.2015
- 16 Giliad. First-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study. Im Internet: http://www.gilead.com/news/press-releases/2014/9/firstline-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study Letzter Zugriff: 9.7.2015